Cue Biopharma Profit Margin

The latest profit margin for CUE is -435.83% as of June 2026. That compares with -469.35% in the prior-year period — up 7.1% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Cue Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CUE's profit margin moved from -469.35% to -435.83% — a 7.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cue Biopharma's valuation or profitability profile.

Against Healthcare companies, CUE currently prints -435.83% for profit margin, while the sector average sits near 13.89%. That is roughly 3237.7% below the sector mean. Large gaps often invite a closer look at Cue Biopharma's growth, margins, and balance sheet.

Profit Margin shows how effectively Cue Biopharma converts resources into returns. At -435.83%, CUE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -469.35% in the prior-year period — up 7.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CUE's profit margin (-435.83%), review year-over-year change from -469.35%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.